On August 28, 2018 Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, reported that it will present a corporate overview at the 2018 Wells Fargo 13th Annual Healthcare Conference, being held on September 5-6 in Boston, MA (Press release, Aeglea BioTherapeutics, AUG 28, 2018, View Source [SID1234529097]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Wells Fargo Healthcare Conference

Aeglea BioTherapeutics Presentation Details

Date: Wednesday, September 5

Time: 10:50 am Eastern Time

Location: The Westin Copley Place, Boston, MA

Webcast: https://cc.talkpoint.com/well001/090518a_as/?entity=51_HGGS50C
To access the live and archived webcast of the presentation, please visit the Presentations & Events section of the Aeglea BioTherapeutics investor relations website. Please connect to the website at least 15 minutes prior to the presentation to allow for any software download that may be necessary. The replay of the webcast will be available for 30 days thereafter.

Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aeglea’s Compensation Committee of its Board of Directors has granted non-qualified stock options to purchase an aggregate of 41,000 shares of Aeglea’s common stock to four new employees under Aeglea’s 2018 Equity Inducement Plan. The 2018 Equity Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Aeglea (or following a bona fide period of non-employment), as an inducement material to such individual’s entering into employment with Aeglea, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules. The options have an exercise price of $10.28 or $10.54 per share, which is equal to the closing price of Aeglea’s common stock on August 24, 2018 or August 27, 2018, respectively. Each of the option awards vests as to 25% of the shares on the one-year anniversary of its grant, with the remainder of the shares vesting ratably over 36 months thereafter.

On August 28, 2018 Incyte Corporation (Nasdaq:INCY) reported that it will present at the Morgan Stanley 16th Annual Global Healthcare Conference on Thursday, September 13, 2018 at 10:00 am EDT in New York (Press release, Incyte, AUG 28, 2018, View Source [SID1234529096]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation and Q&A session will be webcast live and can be accessed at www.incyte.com in the Investors section under "Events and Presentations." Investors interested in listening to the live webcast should log on before the start time in order to download any software required.

On August 28, 2018 Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, reported that members of the management team will participate in three upcoming investor conferences (Press release, Syndax, AUG 28, 2018, View Source [SID1234529095]). The details for the three conferences are:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

B. Riley FBR Healthcare Conference at the New York Marriott East Side on Tuesday, September 4, 2018. Panel discussion at 11:20 a.m. ET.

Citi’s 13th Annual Biotech Conference at the Four Seasons Hotel Boston on Wednesday, September 5, 2018.

Morgan Stanley 16th Annual Global Healthcare Conference at the Grand Hyatt Hotel New York on Friday, September 14, 2018. Fireside chat at 12:15 p.m. ET.

A live webcast of the Morgan Stanley 16th Annual Global Healthcare Conference fireside chat can be accessed from the Investor section of the Company’s website at www.syndax.com, where a replay of the events will also be available for a limited time.

On August 28, 2018 Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), reported that the Company will be presenting at the Rodman & Renshaw 20th Annual Global Investment ConferenceSeptember 4-6, 2018 at The St. Regis New York (Press release, Onconova, AUG 28, 2018, View Source [SID1234529094]). Steven M. Fruchtman, M.D., President and Chief Medical Officer of Onconova, Ramesh Kumar, CEO and Mark Guerin, CFO will attend the conference and be available to meet with investors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation details
Date/Time: Wednesday, September 5th at 3:00p ET
Venue: The St. Regis New York, 2nd Floor: Fontainebleau Room
Presenter: Steven M. Fruchtman, M.D.

On August 28, 2018 NuCana plc (NASDAQ: NCNA) reported that its financial results for the second quarter ended June 30, 2018 and provided an update on its extensive clinical program with its transformative ProTide therapeutics (Press release, Nucana BioPharmaceuticals, AUG 28, 2018, View Source [SID1234529093]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As of June 30, 2018, NuCana had cash and cash equivalents of £81.5 million compared to £81.3 million as of March 31, 2018 and £86.7 million as of December 31, 2017. This increase in cash and cash equivalents during the second quarter of 2018 reflects the weakening of the UK pound sterling relative to the US dollar and the fact that NuCana holds a portion of its cash in US dollars. NuCana reported a loss of £1.3 million for the quarter ended June 30, 2018, compared to £2.7 million for the quarter ended June 30, 2017 as the Company continued to advance its various clinical programs. Basic and diluted loss per share was £0.04 for the quarter ended June 30, 2018, compared to £0.11 per share for the comparable quarter in 2017.

"We have made excellent progress with our development programs during the first half of 2018 and look forward to providing additional clinical updates later in the year," said Hugh Griffith, NuCana’s Founder and Chief Executive Officer. "The high response rates achieved in the first cohort of eight patients with biliary tract cancers, which were reported earlier this year at ASCO (Free ASCO Whitepaper) GI, has led us to prioritize this indication for rapid development. We are also excited about opening our combination Phase 1b study with NUC-3373 for patients with colorectal cancers and taking our third ProTide, NUC-7738, into the clinic later this year."

Mr. Griffith continued: "We are also pleased to announce that we have had three posters accepted for presentation at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress being held in Munich, Germany on October 19 to 23, 2018. These posters include additional data from the ongoing Phase 1b study of Acelarin plus cisplatin in front-line advanced biliary tract cancer (the ABC-08 study), additional data from the ongoing Phase 1 study of NUC-3373 in advanced solid tumors (the NuTide:301 study) and a study status update from the ongoing Phase 3 study of Acelarin compared to gemcitabine in front-line pancreatic cancer patients (the Acelarate study)."

Anticipated Second Half 2018 Milestones

Acelarin is NuCana’s ProTide transformation of gemcitabine. Over the remainder of 2018, NuCana anticipates a number of data read-outs and milestones including:

Reporting additional Phase 1b data of Acelarin combined with cisplatin as a first-line treatment for patients with advanced biliary tract cancer at ESMO (Free ESMO Whitepaper) on October 21, 2018 (the ABC-08 study). This will include additional data on the eight patients reported at ASCO (Free ASCO Whitepaper)-GI in January 2018, data from the six patients in the 725mg/m2 dose cohort, and interim data from the additional six patients in an expansion cohort at the selected 625mg/m2 dose.

Initiating a Phase 3 study of Acelarin combined with cisplatin as a first-line treatment for patients with advanced biliary tract cancer.

Continuing to enroll and follow-up with patients in the Phase 2 platinum-resistant ovarian study (the PRO-105 study).

Reporting current study status of the ongoing Phase 3 study of Acelarin compared to gemcitabine as a first-line treatment of patients with metastatic pancreatic cancer at ESMO (Free ESMO Whitepaper) on October 21, 2018 (the Acelarate study).

NUC-3373 is NuCana’s second ProTide in clinical development, a transformation of 5-fluorouracil (5-FU). In 2018, NuCana expects to:

Report additional Phase 1 data in advanced solid tumors at ESMO (Free ESMO Whitepaper) on October 22, 2018 (the NuTide:301 study).

Initiate a Phase 1b study in patients with advanced colorectal cancer in combination with other approved agents with which 5-FU is typically combined, including leucovorin, oxaliplatin and irinotecan (the NuTide:302 study).

NUC-7738 is NuCana’s ProTide transformation of cordycepin, a novel nucleoside analog that has shown potent anti-cancer activity in preclinical studies across a range of different human cancer cell lines. NuCana expects to initiate a First-In-Human Phase 1 clinical study of NUC-7738 in patients with solid tumors later in 2018 (the NuTide:701 study).